Study: NCT02613013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neodymium:yttrium-aluminum- garnet laser
Description: a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neodymium:yttrium-aluminum- garnet laser
Description: a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser
Description: a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pilocarpine
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LPIP plus LPI
Description: LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proparacaine
Description: 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LPI
Description: LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris \>0.1mm. and patency was determined by direct visualization of the posterior chamber.